According to a regulatory filing Thursday with the Securities and Exchange Commission, Helicos BioSciences Corp. lowered the expected price of its initial public offering for the second time to $9 per share. On Wednesday, Helicos, which is developing a system for genetic analysis, reduced the expected price range of its offering to $10 to $11 per share, from its previous anticipated range of $13 to $15 per share.